Why the study?
Cardiac amyloidosis mimics left ventricular hypertrophy and has a poor prognosis despite being treatable, making a simple screening tool valuable.
Does a risk score incorporating relative apical sparing pattern (RASP) improve screening for cardiac amyloidosis in patients with left ventricular hypertrophy?
Does a risk score incorporating relative apical sparing pattern (RASP) improve screening for cardiac amyloidosis in patients with left ventricular hypertrophy?
A simple risk score incorporating the relative apical sparing pattern on echocardiography provides high diagnostic discrimination for screening cardiac amyloidosis in patients with left ventricular hypertrophy.
BACKGROUND: Cardiac amyloidosis (CA) mimics left ventricular hypertrophy (LVH). It is treatable, but its prognosis is poor. A simple screening tool for CA would be valuable. CA is more precisely diagnosed with echocardiographic deformation parameters (e.g., relative apical sparing pattern [RASP]) than with conventional parameters. We aimed to 1) investigate incremental benefits of echocardiographic deformation parameters over established parameters for CA screening; 2) determine the resultant risk score for CA screening; and 3) externally validate the score in LVH patients. METHODS: Tc-PYP scintigraphy. The base model comprised age (≥65 years [men], ≥70 years [women]), low voltage on the electrocardiogram, and posterior wall thickness ≥ 14 mm in reference to the literature. The incremental benefit of each binarized echocardiographic parameter over the base model was assessed using receiver operating characteristic curve analysis and comparisons of the area under the curve (AUC). RESULTS: Fifty-four (18%) patients had CA. RASP showed the most incremental benefit for CA screening over the base model. After conducting multiple logistic regression analysis for CA screening using four variables (RASP and base model components), a score was determined (range, 0-4 points). The score demonstrated adequate discrimination ability for CA (AUC = 0.86). This result was confirmed in another validation cohort (178 patients, AUC = 0.88). CONCLUSIONS: We developed a score incorporating RASP for CA screening. This score is potentially useful in the risk stratification and management of LVH patients.
No takes yet. Share an insight, caveat, or question.
Nakao et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: